Approval · Notice of Compliance 7342 · 2005
SUMATRYX: Notice of Compliance 7342
Issued September 2, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 7342
- Date
- September 2, 2005
- Company
- Oryx Pharmaceuticals Inc., A Subsidiary Of Filiale D'arrow Pharmaceuticals Inc.Mississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Labelling Only
- Therapeutic class
- 5-ht1 receptor agonist, migraine therapy
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUMATRYX | 02268213 | — |
| SUMATRYX | 02268221 | — |
| SUMATRYX | 02268248 | — |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 25 MG per TAB
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB